Lung Cancer :: GALES Trial of ALIMTA, pemetrexed for injection in Small Cell Lung Cancer

Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent, in direct comparison to the current leading treatment option of etoposide in combination with carboplatin.

Cancer :: Taxotere, docetaxel by Sanofi-Aventis for Advanced Head and Neck Cancer

The Food and Drug Administration (FDA) approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). This disease represents approximately 3 percent of all new cancer cases in the United States.

Stroke :: Surgery Better Than Stents

Surgery outperformed the use of stents in a French trial of patients who had warning symptoms of stroke because of blockage of the carotid arteries, the main blood vessels to the brain. Indeed, the trial was cut short “for reasons of both safety and futility,” said a report in the Oct. 19 issue of the New England Journal of Medicine. The incidence of stroke or death in the 30 days and six months after a procedure was about twice as high for patients given a stent, a tube-like device to keep an artery open, than for those who had the surgery called endarterectomy.

Health :: New mechanism found that may underlie neuropathic pain

Researchers at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) announced on 15 October 2006 that they have discovered a new molecular mechanism that may underlie neuropathic pain. The clearer understanding of the root-cause of chronic neuropathic pain, and the preclinical validation of new targets for pharmaceutical therapies shown in this research, together present an opportunity for the development of new ways to treat the severe pain associated with such common conditions or diseases as sciatica, diabetic neuropathy and shingles.

Brain Tumor :: Children’s hospital Boston neurosurgeons to perform brain tumor removal during live webcast

On Wednesday, Oct. 25, at 1:00 p.m. EDT, neurosurgeons at Children’s Hospital Boston will remove a brain tumor employing functional mapping of the cortex on a 13-year-old pediatric patient during a live Webcast. Children’s hosts three to four Webcasts annually to showcase its pioneering care and technology to specialists and referring physicians around the world, and to educate consumers on the latest and most innovative medical treatments available.

Cancer :: Methoxyamine – new cancer therapy reverses resistance to chemotherapy

Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.

Health :: Using neurofeedback to aid medical patients

A new article reviews the literature of quantitative electroencephalography (QEEG) that documents abnormal brain wave patterns accompanying several medical conditions. The research implies that neurofeedback training may partially or fully normalize these brain wave patterns, and improve the physical and mental functioning of people with these conditions. The article is in the latest issue of Biofeedback.

Lip Implant :: Lip augmentation decreases appearance of ageing

Lip augmentation is not just for women who want larger, sexier lips. As people age, their lips lose fullness which makes them appear older. While injectable fillers can combat aging around the lips and mouth, not all are created equal – some can even lead to long-lasting complications, say presenters at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2006 conference in San Francisco.

Breast Reduction :: Insurance companies deny medically necessary breast reductions

What if you couldn’t perform daily activities, such as exercising or running with your children, because of overly large breasts that caused unending pain? Despite existing scientific studies that outline the medical necessity for breast reduction, many insurance companies are denying thousands of women the procedure each year because of rigid, unfounded conditions to secure coverage, according to a study presented at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2006 conference in San Francisco.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack